ArticleOncoTargets and therapy2021

Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice.

Mª Del Carmen Álamo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.